Cupid secures CE certification for pregnancy, syphilis test kits

Cupid Limited announced on October 18, 2025, that it has secured CE (EU IVDR) Certification for its CupiSURE Pregnancy (hCG) Test Kit and CupiKIT Syphilis Antibody Test Kit. These certifications validate compliance with EU Regulation (EU) 2017/746 (IVDR), enabling Cupid to distribute these in-vitro diagnostic (IVD) devices across the European Economic Area and other CE-recognized global markets. This move diversifies Cupid's offerings beyond sexual health products into preventive and diagnostic healthcare.

The newly certified kits target significant market opportunities. The global pregnancy (hCG) test kit market, valued at $1.7 bn in 2024, is projected to reach $2.9 bn by 2034. Similarly, the syphilis immunoassay diagnostics market, estimated at $611m in 2025, is expected to grow to $993m by 2034.

Cupid is also in the final stages of obtaining CE (EU IVDR) Certification for its HIV 1 & 2 Antibody and Hepatitis B Antigen IVD kits by December 2025. The HIV 1 & 2 Antibody diagnostics market is estimated at $3.6 bn in 2025, projected to expand to $6.1 bn by 2030, while the Hepatitis B Antigen IVD diagnostics market, valued at $1.3 bn in 2024, is expected to surpass $2.0 bn by 2033.